Released Aug 8, 2019, after the close
10-Q filed Aug 8, 2019, 39 days after period end · 0001564590-19-030746
Q2 2019 · 10-Q
Revenue$67.00K$67.00K −85.5% vs Q2 2018−98.2% vs Q1 2019
Net Income-$13.20M-$13.20M N/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.74-$0.74 N/M vs Q2 2018N/M vs Q1 2019
Operating Income-$13,652,000N/M
Operating Cash Flowderived-$12,070,000N/M
Free Cash Flowderived-$12,157,000—
Margins · derived
Operating margin-20376.1%−18222.6 pt vs Q2 2018
Net margin-19701.5%−17551.2 pt vs Q2 2018
What the release said
The release
Same quarter
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Revenue | $67.00K | $463.00K | $249.00K | — |
| Net Income | -$13.20M | -$9.96M | -$9.17M | -$6.06M |
| EPS Diluted | -$0.74 | -$0.69 | -$36.21 | -$25.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR